fda compounding semaglutide crackdown news today 2025 is short-sighted on GLP-1s Compounding pharmacies to halt semaglutide

Improved Glycemic Control: It has shown clinically meaningful improvements in blood sugar control (HbA1c levels) in patients with type 2 diabetes

This metabolic slowdown makes continued weight loss increasingly difficult

A positive readout would allow submission of an NDA to the FDA, with approval possibly following in 2027 and commercial availability shortly after

Although retatrutide is not yet available outside of clinical trials, the factors that influence starting dose and titration speed are broadly consistent with those applied to similar licensed medicines

Frequently Asked Questions What temperature should reconstituted retatrutide be stored at

Absence of glucagon and insulin action reveals a role for the GLP-1 receptor in endogenous glucose production